Biography
Eduard H Panosyan is a Pediatric Hematologist-Oncologist, who as a Physician-Scientist developed his initial research expertise in studying amino acid metabolism in childhood acute lymphoblastic leukemias. His further research skills are related to studies of pediatric brain tumors. Consequentially, as an Independent Investigator, he has developed research interests on metabolic pathways and related cellular mechanisms by which brain tumor cells sustain malignant proliferation in vitro and in vivo. Main focus of his investigations is on augmented metabolism of amino acids promoting progression of malignant brain tumors. Identification of druggable targets for heterogeneous metabolic patterns in glioblastomas and medulloblastomas may allow effective therapeutics development. His lab is on the verge of conducting exciting pre-clinical experiments to test some of the anti-metabolites with chemotherapy against intracranial brain tumors.
Abstract
Statement of the Problem: Brain tumors cause major morbidity/mortality. Glioblastoma (GBM) in adults and medulloblastoma in children are major types of clinically aggressive high-grade CNS malignancies. These have increased uptake of radio-labeled amino-acids (AA) used for PET scans. Central amino-acid Glutamine (Gln) is crucial for growth of brain tumors. Nevertheless, there aren’t clinically effective pharmaceutical interventions against AA metabolism of brain tumors. In contrary, anti-metabolites like bacterial enzyme asparaginase (ASNase, which effectively depletes asparagine and Gln in blood and CSF) are successfully used to treat acute leukemias. Thus, we aimed to study if manipulation of AA metabolism may have a role in developing therapeutics against brain tumors. Methodology & Theoretical Orientation: We conducted series of analyses on large brain tumor databases containing molecular signatures and clinical outcomes. In addition, using ASNase as a research tool, we carried out series of pre-clinical investigations on glioma cell-lines and on mice that harbor medulloblastomas. Findings: We have shown that lower co-expressions of BCAT1, ASNS and GLS are associated with better outcome in 66 newly diagnosed GBM patients (UCLA-probesetanalyzer database). Three additional GBM datasets (r2.amc.nl) showed that at least 4 additional AA-related enzymes-which have higher expression in GBM, also predict poor outcome in 504 GBM patients (TCGA database). Several of these enzymes have differential expression in pediatric brain tumors, including subtypes of medulloblastomas. Mouse models of medulloblastomas demonstrated anti-tumor efficacy of E. coli-ASNase+TMZ against DAOY-SQ model and of Erwinia Chrysanthemi-ASNase, which shows preliminary efficacy in SMO/SMO spontaneous medulloblastoma model. All ASNase formulations showed in vitro activity against glioma cells with variable IC50s. Conclusion & Significance: Our studies support the concept that AA metabolism plausibly harbors targetable nodes, which can be studied for new anti-metabolite therapeutics development for brain tumors. They provide opportunities for combined therapies due to less myelosuppressive toxicity profile.
Biography
Alexandra Kasabova received his Master’s degree in Faculty of Pharmacy at Medical University–Sofia, in November 2014. She is a PhD student at the Department of Pharmacology, Pharmacotherapy and Toxicology, Medical University-Sofia from November 2015 until now. She has interests in the field of neuropharmacology and has experimental works on neuronal cell line SH-SY5Y and synaptosomal fraction in normal state and in condition of 6-OHDA–induced oxidative stress
Abstract
Certain asymmetrically substituted xanthines (propentofylline) are used to treat CNS disorders such as dementia in Alzheimer's disease. In the present study, we investigated the toxicity of 14 newly synthesized derivatives of caffeine-8-α-methyl thioglycolic acid (Jα-0 to Jα-13) on human neuroblastoma derived cells in vitro. The protective effects of the less cytotoxic compounds were also studied in 6-hydroxydopamine (6-OHDA) induced oxidative stress in neuroblastoma SH-SY5Y cells. To evaluate the effects of the treatment, SH-SY5Y cells viability (measured by MTT-test) was used as markers of oxidative damage. SH-SY5Y cells are often used for studying the processes of neurotoxicity and neurodegenerative diseases, such as Parkinson’s. The cells possess the ability to synthesize dopamine and express dopamine transporter (DAT), a protein expressed only in dopaminergic neurons within the central nervous system. Administered alone, all compounds revealed statistically significant toxic effects, compared to the control (untreated cells). Three of the compounds, Jα-6, Jα-7 and Jα-9, had lower neurotoxic effects: Jα-6 decreased cell viability by 10 %, Jα-7 –by 15% and Jα-9–by 14% (vs. control). All other compounds showed higher cytotoxicity towards SH-SY5Y, decreasing cell viability in the range of 18% to 29%. In a model of 6-OHDA-induced oxidative stress on SH-SY5Y only Jα-7 and Jα-9 (100 μM) revealed statistically significant neuroprotective effects, shown by preservation of the cell viability. In particular, Jα-9 preserved the cell viability by 150% and Jα-7– by 91%, compared to 6-OHDA. Jα-6 had no statistically significant protective effect, compared to 6-OHDA.